AstraZeneca: J&J's Lung Cancer Combo Bests AstraZeneca's Tagrisso, Reducing Risk of Death 25%

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso on overall survival. But analysts say the next step is getting a subcutaneous formula approved.